Literature DB >> 33594150

Effects of open-label placebos in clinical trials: a systematic review and meta-analysis.

Melina von Wernsdorff1,2, Martin Loef3, Brunna Tuschen-Caffier2, Stefan Schmidt4,5.   

Abstract

Open-label placebos (OLPs) are placebos without deception in the sense that patients know that they are receiving a placebo. The objective of our study is to systematically review and analyze the effect of OLPs in comparison to no treatment in clinical trials. A systematic literature search was carried out in February 2020. Randomized controlled trials of any medical condition or mental disorder comparing OLPs to no treatment were included. Data extraction and risk of bias rating were independently assessed. 1246 records were screened and thirteen studies were included into the systematic review. Eleven trials were eligible for meta-analysis. These trials assessed effects of OLPs on back pain, cancer-related fatigue, attention deficit hyperactivity disorder, allergic rhinitis, major depression, irritable bowel syndrome and menopausal hot flushes. Risk of bias was moderate among all studies. We found a significant overall effect (standardized mean difference = 0.72, 95% Cl 0.39-1.05, p < 0.0001, I2 = 76%) of OLP. Thus, OLPs appear to be a promising treatment in different conditions but the respective research is in its infancy. More research is needed, especially with respect to different medical and mental disorders and instructions accompanying the OLP administration as well as the role of expectations and mindsets.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33594150      PMCID: PMC7887232          DOI: 10.1038/s41598-021-83148-6

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  50 in total

Review 1.  A comprehensive review of the placebo effect: recent advances and current thought.

Authors:  Donald D Price; Damien G Finniss; Fabrizio Benedetti
Journal:  Annu Rev Psychol       Date:  2008       Impact factor: 24.137

2.  RoB 2: a revised tool for assessing risk of bias in randomised trials.

Authors:  Jonathan A C Sterne; Jelena Savović; Matthew J Page; Roy G Elbers; Natalie S Blencowe; Isabelle Boutron; Christopher J Cates; Hung-Yuan Cheng; Mark S Corbett; Sandra M Eldridge; Jonathan R Emberson; Miguel A Hernán; Sally Hopewell; Asbjørn Hróbjartsson; Daniela R Junqueira; Peter Jüni; Jamie J Kirkham; Toby Lasserson; Tianjing Li; Alexandra McAleenan; Barnaby C Reeves; Sasha Shepperd; Ian Shrier; Lesley A Stewart; Kate Tilling; Ian R White; Penny F Whiting; Julian P T Higgins
Journal:  BMJ       Date:  2019-08-28

3.  Informed consent and clinical trials: where is the placebo effect?

Authors:  C R Blease; F L Bishop; T J Kaptchuk
Journal:  BMJ       Date:  2017-02-03

4.  Altered placebo and drug labeling changes the outcome of episodic migraine attacks.

Authors:  Slavenka Kam-Hansen; Moshe Jakubowski; John M Kelley; Irving Kirsch; David C Hoaglin; Ted J Kaptchuk; Rami Burstein
Journal:  Sci Transl Med       Date:  2014-01-08       Impact factor: 17.956

Review 5.  Placebos Without Deception: Outcomes, Mechanisms, and Ethics.

Authors:  Luana Colloca; Jeremy Howick
Journal:  Int Rev Neurobiol       Date:  2018-04-04       Impact factor: 3.230

Review 6.  Effects of placebos without deception compared with no treatment: A systematic review and meta-analysis.

Authors:  James E G Charlesworth; Grace Petkovic; John M Kelley; Monika Hunter; Igho Onakpoya; Nia Roberts; Franklin G Miller; Jeremy Howick
Journal:  J Evid Based Med       Date:  2017-05

7.  Open-label placebo clinical trials: is it the rationale, the interaction or the pill?

Authors:  Charlotte R Blease; Michael H Bernstein; Cosima Locher
Journal:  BMJ Evid Based Med       Date:  2019-06-26

8.  Open-label placebo reduces fatigue in cancer survivors: a randomized trial.

Authors:  Eric S Zhou; Kathryn T Hall; Alexis L Michaud; Jaime E Blackmon; Ann H Partridge; Christopher J Recklitis
Journal:  Support Care Cancer       Date:  2018-10-10       Impact factor: 3.603

9.  Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta-analysis.

Authors:  T A Furukawa; H Noma; D M Caldwell; M Honyashiki; K Shinohara; H Imai; P Chen; V Hunot; R Churchill
Journal:  Acta Psychiatr Scand       Date:  2014-04-04       Impact factor: 6.392

View more
  14 in total

1.  How orthopedic surgeons view open label placebo pills: Ethical and effective, but opposed to personal use.

Authors:  Michael H Bernstein; Maayan Rosenfield; Nathaniel Fuchs; Molly Magill; Charlotte R Blease; Francesca L Beaudoin; Josiah D Rich; Karolina Wartolowska; Richard M Terek
Journal:  J Psychosom Res       Date:  2021-10-05       Impact factor: 3.006

2.  Placebos in clinical care: a suggestion beyond the evidence.

Authors:  Christopher G Maher; Adrian C Traeger; Christina Abdel Shaheed; Mary O'Keeffe
Journal:  Med J Aust       Date:  2021-09-19       Impact factor: 12.776

3.  Psychological Predictors of Response to Open-Label Versus Double-Blind Placebo in a Randomized Controlled Trial in Irritable Bowel Syndrome.

Authors:  Sarah Ballou; Julia W Haas; Johanna Iturrino; Judy Nee; Irving Kirsch; Vikram Rangan; Vivian Cheng; Anthony Lembo; Ted J Kaptchuk; John M Kelley
Journal:  Psychosom Med       Date:  2022-04-12       Impact factor: 3.864

4.  Lay perspectives of the open-label placebo rationale: a qualitative study of participants in an experimental trial.

Authors:  Cosima Locher; Sarah Buergler; Antje Frey Nascimento; Linda Kost; Charlotte Blease; Jens Gaab
Journal:  BMJ Open       Date:  2021-08-18       Impact factor: 3.006

5.  Open-Label Placebo Administration Decreases Pain in Elderly Patients With Symptomatic Knee Osteoarthritis - A Randomized Controlled Trial.

Authors:  Elisabeth Olliges; Sabine Stroppe; Anja Haile; Fabienne Reiß; Marwa Malhis; Susanne A Funke; Karin Meissner
Journal:  Front Psychiatry       Date:  2022-05-06       Impact factor: 5.435

6.  Open-Label Placebo Interventions With Drinking Water and Their Influence on Perceived Physical and Mental Well-Being.

Authors:  Marco Rathschlag; Stefanie Klatt
Journal:  Front Psychol       Date:  2021-12-06

7.  Role of hyperpolarization-activated cyclic nucleotide-gated ion channels in neuropathic pain: a proof-of-concept study of ivabradine in patients with chronic peripheral neuropathic pain.

Authors:  Shannon A Bernard Healey; Ingrid Scholtes; Mark Abrahams; Peter A McNaughton; David K Menon; Michael C Lee
Journal:  Pain Rep       Date:  2021-10-18

8.  Patients' experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative study.

Authors:  Julia W Haas; Giulio Ongaro; Eric Jacobson; Lisa A Conboy; Judy Nee; Johanna Iturrino; Vikram Rangan; Anthony Lembo; Ted J Kaptchuk; Sarah Ballou
Journal:  BMC Psychol       Date:  2022-02-04

9.  Placebo Responses and Their Clinical Implications in Fibromyalgia: A Meta-Analysis Using SSRI and SNRI Trials.

Authors:  Helen Koechlin; Anna Kharko; Tamara Probst; Julia Pradela; Stefan Buechi; Cosima Locher
Journal:  Front Pain Res (Lausanne)       Date:  2021-12-07

10.  Editorial: Placebo Effect in Pain and Pain Treatment.

Authors:  Michael H Bernstein; Charlotte Blease; Lene Vase
Journal:  Front Pain Res (Lausanne)       Date:  2022-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.